06:10 EDT Travere falls 14% to $18.10 after FDA does not grant priority review
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics selloff should be bought, says Citi
- Buy Rating Reaffirmed for Travere Therapeutics Amid FDA Review and Market Overreaction
- Closing Bell Movers: Applied Materials down over 5% after Q2 results
- Travere Therapeutics’ FDA Acceptance for FILSPARI Application
- Travere Therapeutics announces FDA acceptance of sNDA for Filspari